| 中文名 | (2S,3R,4R,5S,6R)-2-(7-氯-6-(4-环丙基苄基)-2,3-二氢苯并呋喃-4-基)-6-(羟甲基)四氢-2H-吡喃-3,4,5-三醇 |
|---|---|
| 英文名 | (1S)-1,5-Anhydro-1-[7-chloro-6-(4-cyclopropylbenzyl)-2,3-dihydro-1-benzofuran-4-yl]-D-glucitol |
| 英文别名 |
DWP-16001
agent,sodium-glucose,Enavogliflozin,inhibit,selective,SGLT,DWP 16001,orally,Inhibitor,cotransporter,Sodium-dendent glucose cotransporters,antidiabetic,DWP16001 (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclopropylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol Enavogliflozin(DWP-16001) D-Glucitol, 1,5-anhydro-1-C-[7-chloro-6-[(4-cyclopropylphenyl)methyl]-2,3-dihydro-4-benzofuranyl]-, (1S) Enavogliflozin, 10 mM in DMSO Afacifenacin Impurity 4 |
| 描述 | 依那伏格列嗪(DWP-16001)是一种抗糖尿病药物,是一种口服活性最佳的选择性钠-葡萄糖协同转运蛋白-2(SGLT-2)抑制剂[1][2][3]。 |
|---|---|
| 相关类别 | |
| 靶点 |
SGLT2 |
| 体外研究 | 依那伏格列嗪(DWP-16001)是一种抗糖尿病药物,是一种口服活性最佳的选择性钠-葡萄糖协同转运蛋白-2(SGLT-2)抑制剂[1][2][3]。 |
| 参考文献 |
[1]. Daewoong speeds up developing antidiabetic Enavogliflozin [2]. These are the results of clinical trials of the diabetes drug Enavogliflozin and Metformin |
| 密度 | 1.4±0.1 g/cm3 |
|---|---|
| 沸点 | 666.1±55.0 °C at 760 mmHg |
| 分子式 | C24H27ClO6 |
| 分子量 | 446.92 |
| 闪点 | 356.7±31.5 °C |
| 精确质量 | 446.149628 |
| LogP | 4.90 |
| 蒸汽压 | 0.0±2.1 mmHg at 25°C |
| 折射率 | 1.666 |